Current Report Filing (8-k)
July 22 2019 - 8:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 20, 2019
Date of Report (Date of earliest event reported)
MARKER
THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37939
|
45-4497941
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
3200 Southwest Freeway
Suite 2240
Houston, Texas
|
|
77027
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(713) 400-6400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
MRKR
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01.
|
Regulation FD Disclosure.
|
On July 22, 2019, Marker Therapeutics,
Inc. (the “Company”) hosted a live webcast featuring Brandon G. Smaglo, M.D., FACP, lead investigator and
Assistant Professor of Oncology at the Baylor College of Medicine, Houston, Texas, and the
Company’s senior management to discuss interim results from an investigator-sponsored clinical trial led by Baylor
College of Medicine evaluating the Company’s MultiTAA therapy for the treatment of patients with
pancreatic adenocarcinoma (the “Clinical Trial”). A copy of the slides presented during the webcast is furnished
herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 of this
Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing
with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of
any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
On July 20, 2019, the Company issued a press
release announcing interim results from the Clinical Trial. A copy of the press release is attached hereto as Exhibit 99.2 and
is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
In accordance with the requirements of the
Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this
22
nd
day of July, 2019.
|
MARKER THERAPEUTICS, INC.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Anthony Kim
|
|
|
Anthony Kim
|
|
|
Chief Financial Officer
|
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024